NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: BAJAJHCARE · data 2026-11-01
Bajaj Healthcare Ltd
In plain words
Price: 36.4% below its 52-week high of ₹481.8.
Delivery: 45.5% of traded shares were kept for delivery over the last 10 sessions, against 48.6% over the last 60.
Latest results: a net profit of ₹14 cr for the quarter ended Sept 2026 (+26.8% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹656 cr |
| Net profit (last 12 months) | ₹21 cr |
| Sales growth, 3 years (yearly) | -1.8% |
| Profit growth, 3 years (yearly) | -28.4% |
At a glance
Promoters 58.6% (-0.6 pts in a year), pledged 0.0%, institutions 4.0%.
P/E 51.5, P/B 1.9, dividend yield 0.5%. Price relative to earnings and book value (low is cheaper, not better).
ROE 4.3%, ROCE 13.2%, operating margin 12.8%: how much profit it earns on the money it uses.
Debt/equity 0.47, Profit growth -28.4% and sales growth -1.8% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (4.3%).
- Profit fell 28.4% a year over 3 years.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
BAJAJHCARE Q2 FY27 results (standalone figures, as filed on NSE).
Revenue was ₹175.9 crore, up 18.9% YoY and up 6.2% QoQ.
Net profit was ₹14.09 crore, up 26.8% YoY and up 2.8% QoQ.
Operating margin was 17.7% (18.2% a year ago).
EPS was ₹4.19, up 18.7% YoY and up 2.9% QoQ.
BAJAJHCARE के Q2 FY27 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹175.9 करोड़; पिछले साल की तुलना में 18.9% की बढ़त, पिछली तिमाही की तुलना में 6.2% की बढ़त।
शुद्ध मुनाफ़ा: ₹14.09 करोड़; पिछले साल की तुलना में 26.8% की बढ़त, पिछली तिमाही की तुलना में 2.8% की बढ़त।
ऑपरेटिंग मार्जिन: 17.7% (एक साल पहले 18.2%)।
EPS: ₹4.19; पिछले साल की तुलना में 18.7% की बढ़त, पिछली तिमाही की तुलना में 2.9% की बढ़त।
BAJAJHCAREના Q2 FY27 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹175.9 કરોડ; ગયા વર્ષની સરખામણીએ 18.9% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 6.2% વધારો.
ચોખ્ખો નફો: ₹14.09 કરોડ; ગયા વર્ષની સરખામણીએ 26.8% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 2.8% વધારો.
ઓપરેટિંગ માર્જિન: 17.7% (એક વર્ષ પહેલાં 18.2%).
EPS: ₹4.19; ગયા વર્ષની સરખામણીએ 18.7% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 2.9% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
11/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 6/30: Delivery 47.2% over the last 20 sessions vs 46.3% in the 40 before (1.02x); shares delivered per day 1.22x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 17 Oct 26Results Q2 FY27 results: profit +26.8% YoY -0.8% next session
- 11 Sept 26Dividend Dividend ₹1.5 (ex-date) -3.7% next session
- 20 Jul 26Results Q1 FY27 results: profit +15.8% YoY -1.2% next session
- 8 May 26Results Q4 FY26 results: turned to loss vs a year ago -10.4% next session
- 16 Jan 26Results Q3 FY26 results: profit +33.7% YoY -0.6% next session
- 17 Oct 25Results Q2 FY26 results: profit +17.4% YoY -4.1% next session
- 19 Sept 25Dividend Dividend ₹1 (ex-date) -1.5% next session
- 28 Jul 25Results Q1 FY26 results: profit +65.9% YoY -0.1% next session
- 27 May 25Results Q4 FY25 results: turned to profit vs a year ago -7.6% next session
- 12 Feb 25Results Q3 FY25 results: turned to profit vs a year ago +6.2% next session
- 15 Nov 24Results Q2 FY25 results: turned to profit vs a year ago -2.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹176 cr | ₹14 cr | +26.8% | 17.7% | 4.19 |
| Jun 2026 | ₹166 cr | ₹14 cr | +15.8% | 17.4% | 4.07 |
| Mar 2026 | ₹153 cr | ₹-23 cr | -304.4% | 14.8% | -7.16 |
| Dec 2025 | ₹161 cr | ₹16 cr | +33.7% | 19.0% | 4.96 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 58.59% | 58.59% | 58.29% | 59.19% |
| Foreign institutions (FII) | 2.09% | 2.19% | 1.98% | 1.18% |
| Domestic institutions (DII) | 1.96% | 1.92% | 2.91% | 2.96% |
| Mutual funds | 1.69% | 1.69% | 1.69% | 1.66% |
| Retail investors | 23.88% | 22.63% | 20.58% | 21.07% |
| Number of shareholders | 40,754 | 41,310 | 38,158 | 37,953 |
Common questions
What was Bajaj Healthcare Ltd's latest quarterly profit?
Bajaj Healthcare Ltd reported a net profit of ₹14 cr for the quarter ended Sept 2026 (+26.8% on the same quarter a year earlier), on revenue of ₹176 cr.
How much do promoters hold in Bajaj Healthcare Ltd?
Promoters held 58.59% of Bajaj Healthcare Ltd at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Bajaj Healthcare Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.47.
What is Bajaj Healthcare Ltd's P/E ratio?
About 51.5, based on the last 12 months' earnings and a price of ₹306.3 (data 2026-11-01).
What is the 52-week high and low of Bajaj Healthcare Ltd?
The 52-week high is ₹481.8 and the 52-week low is ₹272.35.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Bajaj Healthcare Ltd | ₹306.3 | ₹1,031 cr | 51.5 | 1.9 | 4.3% | 13.2% | 0.47 | -33.3% |
| Kopran Limited | ₹239.05 | ₹1,156 cr | 46.2 | — | 4.9% | 10.1% | 0.29 | +43.2% |
| Bafna Pharmaceuticals Limited | ₹447.9 | ₹1,060 cr | 136.1 | — | 12.3% | 9.2% | 0.39 | +218.1% |
| Sigachi Industries Limited | ₹26.36 | ₹1,009 cr | 39.7 | — | -14.6% | 6.1% | 0.31 | -29.4% |
| Lincoln Pharmaceuticals Ltd | ₹499.3 | ₹1,005 cr | 10.4 | — | 12.3% | 10.9% | 0.01 | -5.8% |
| Remus Pharmaceuticals Ltd. | ₹843.35 | ₹994 cr | 26.9 | 2.8 | 12.2% | 14.7% | 0.08 | +27.8% |
Compare BAJAJHCARE with KOPRAN in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open BAJAJHCARE in NSE Scanner →